Portal de Periódicos da CAPES

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

2007; Springer Nature; Volume: 62; Issue: 2 Linguagem: Inglês

10.1038/sj.ejcn.1602748

1476-5640

D-F Ma, L-Q Qin, P-Y Wang, Ryohei Katoh,

Folate and B Vitamins Research

To clarify the effects of isoflavone intake on bone resorption and bone formation. We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed on MEDLINE (January 1966–April 2006), the Cochrane Controlled Trials Register, EMBASE (1985–January 2006), Science Citation Index and PUBMED (updated till April 2006). Nine studies with a total of 432 subjects were selected for meta-analysis. The urinary Dpyr concentration in subjects who consumed isoflavones decreased significantly by −2.08 nmol/mmol (95% confidence interval (CI): −3.82 to −0.34 nmol/mmol) in comparison with that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake significantly increased serum BAP by 1.48 μg/l (95% CI: 0.22–2.75 μg/l). Decreases in the urinary Dpyr concentration with isoflavone intake of <90 mg/day and with treatment lasting less than 12 weeks were −2.34 nmol/mmol (95% CI: −4.46 to −0.22 nmol/mmol) and −2.03 nmol/mmol (95% CI: −3.20 to −0.85 nmol/mmol), respectively. Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if <90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.